Nizoral is a brand name for the medication ketoconazole, which is an antifungal medication used to treat fungal and yeast infections of the skin, scalp, and nails. Here is some information about Nizoral:


Treatment of Fungal Infections

Nizoral (ketoconazole) is primarily prescribed for the treatment of various fungal infections, such as athlete’s foot (tinea pedis), ringworm (tinea corporis), jock itch (tinea cruris), and seborrheic dermatitis. It works by inhibiting the growth and reproduction of the fungi responsible for these infections.

Dosage and Application

Nizoral is available in different formulations, including shampoo, cream, and oral tablets. The specific form prescribed will depend on the type and location of the fungal infection. The medication should be used as directed by a healthcare professional, and it is important to follow the recommended dosage and application instructions.

For scalp conditions, Nizoral shampoo is typically used two to three times a week, lathered into the scalp, and left on for a few minutes before rinsing. Cream formulations are generally applied to the affected area of the skin once or twice daily. Oral tablets are prescribed for more severe or systemic fungal infections and are taken according to the prescribed dosage schedule.

Duration of Treatment

The duration of Nizoral treatment will depend on the specific fungal infection and its severity. In some cases, shorter treatment durations of a few weeks may be sufficient, while other infections may require longer treatment periods. It is important to complete the full course of treatment as prescribed, even if the symptoms improve, to ensure the complete eradication of the fungus.

Precautions and Potential Side Effects

Nizoral is generally well-tolerated, but some individuals may experience mild side effects such as skin irritation, itching, or a burning sensation at the application site. Rarely, more serious side effects such as allergic reactions or liver problems may occur. It is important to report any unusual or severe side effects to a healthcare professional.

Nizoral may interact with certain medications, so it is important to inform your healthcare professional about all the medications you are currently taking.

Consultation with Healthcare Professional

Nizoral is a prescription medication, and its use should be supervised by a healthcare professional. It is important to consult with a doctor or dermatologist to evaluate the specific fungal infection, determine the appropriate treatment plan, and discuss the usage and potential side effects of Nizoral.

WARNING: Please consult with a healthcare professional or doctor for personalized advice and guidance regarding the use of Nizoral or any other antifungal medication for the treatment of fungal infections. They will be able to provide specific instructions based on your medical history and individual needs.


  1. ^ “Ketoconazole”Merriam-Webster Dictionary.
  2. ^ “Ketoconazole” Unabridged (Online). n.d.
  3. ^ “Ketoconazole HRA 200mg Tablets – Summary of Product Characteristics (SmPC)”(emc). 18 September 2017. Retrieved 1 April 2020.
  4. ^ “Ketoconazole 2% w/w Shampoo – Summary of Product Characteristics (SmPC)”(emc). 5 October 2015. Retrieved 1 April 2020.
  5. Jump up to:a b Millikan LE (19 April 2016). Drug Therapy in Dermatology. CRC Press. pp. 82–. ISBN 978-0-203-90831-0.
  6. Jump up to:a b c “Assessment report: Ketoconazole HRA” (PDF). European Medicines Agency. Committee for Medicinal Products for Human Use. Archived (PDF) from the original on 27 August 2016. Retrieved 26 August 2016.
  7. Jump up to:a b Arakaki R, Welles B (February 2010). “Ketoconazole enantiomer for the treatment of diabetes mellitus”. Expert Opinion on Investigational Drugs19 (2): 185–94. doi:10.1517/13543780903381411PMID 20047506S2CID 26531459.
  8. Jump up to:a b c d e f g h “Ketoconazole Monograph for Professionals” American Society of Health-System Pharmacists. Retrieved 23 March 2019.
  9. Jump up to:a b c British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1198. ISBN 9780857113382.
  10. Jump up to:a b c d e f g h “FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems”FDA Drug Safety CommunicationU.S. Food and Drug Administration. 26 July 2013. Archived from the original on 2 December 2013. Retrieved 23 November 2013.
  11. Jump up to:a b c Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 503. ISBN 9783527607495.
  12. ^ “The Top 300 of 2020”ClinCalc. Retrieved 7 October 2022.
  13. ^ “Ketoconazole – Drug Usage Statistics”ClinCalc. Retrieved 7 October 2022.
  14. ^ “Oral ketoconazole (Nizoral) 200 mg tablets”Therapeutic Goods Administration (TGA). 10 October 2013. Retrieved 23 March 2019.
  15. Jump up to:a b c d e f g h i Gupta AK, Lyons DC (2015). “The Rise and Fall of Oral Ketoconazole”. Journal of Cutaneous Medicine and Surgery19 (4): 352–7. doi:10.1177/1203475415574970PMID 25775613S2CID 206695486.
  16. ^ “国家食品药品监督管理总局关于停止生产销售使用酮康唑口服制剂的公告(2015年第85号)” (in Chinese). China Food and Drug Administration. 25 June 2015. Archived from the original on 2 July 2015. Retrieved 2 July 2015.
  17. Jump up to:a b c Phillips RM, Rosen T (2013). “Topical Antifungal Agents”. In Wolverton SE (ed.). Comprehensive Dermatologic Therapy (3rd ed.). Philadelphia: Saunders. pp. 460–472. ISBN 978-1-4377-2003-7.
  18. ^ Neider R, Fritsch PO (2012). “Other Eczematous Eruptions”. In Bolognia JL (ed.). Dermatology (3rd ed.). Philadelphia: Saunders. pp. 219–221. ISBN 9780723435716.
  19. ^ Young BK, Brodell RT, Cooper KD (2013). “Therapeutic Shampoos”. In Wolverton SE (ed.). Comprehensive Dermatologic Therapy (3rd ed.). Philadelphia: Saunders. pp. 562–569. ISBN 978-1-4377-2003-7.
  20. Jump up to:a b c d Finkel R, Cubeddu LX, Clark MA (2009). Pharmacology (4th ed.). Baltimore: Lippincott Williams & Wilkins. p. 411.
  21. ^ Kauffman CA (2004). “Introduction to the Mycoses”. In Goldman L, Ausiello D (eds.). Cecil Textbook of Medicine (22nd ed.). Philadelphia: Saunders. p. 2043ISBN 978-0-7216-9652-2.
  22. Jump up to:a b c d e f g h i Becker KL (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 1197–. ISBN 978-0-7817-1750-2.
  23. ^ McElwee KJ, Shapiro JS (June 2012). “Promising therapies for treating and/or preventing androgenic alopecia”Skin Therapy Letter17 (6): 1–4. PMID 22735503Archived from the original on 12 December 2015.
  24. ^ Piérard-Franchimont C, De Doncker P, Cauwenbergh G, Piérard GE (1998). “Ketoconazole shampoo: effect of long-term use in androgenic alopecia”. Dermatology196 (4): 474–7. doi:10.1159/000017954PMID 9669136S2CID 30635892.
  25. ^ Piérard-Franchimont C, Goffin V, Henry F, Uhoda I, Braham C, Piérard GE (October 2002). “Nudging hair shedding by antidandruff shampoos. A comparison of 1% ketoconazole, 1% piroctone olamine and 1% zinc pyrithione formulations”International Journal of Cosmetic Science24 (5): 249–56. doi:10.1046/j.1467-2494.2002.00145.xhdl:2268/11902PMID 18498517.
  26. ^ Khandpur S, Suman M, Reddy BS (August 2002). “Comparative efficacy of various treatment regimens for androgenetic alopecia in men”. The Journal of Dermatology29 (8): 489–98. doi:10.1111/j.1346-8138.2002.tb00314.xPMID 12227482S2CID 20886812.
  27. ^ Marks DH, Prasad S, De Souza B, Burns LJ, Senna MM (December 2019). “Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris”. Am J Clin Dermatol21 (2): 245–254. doi:10.1007/s40257-019-00493-zPMID 31832993S2CID 209331373.
  28. ^ “MedScape”Ectopic Cortisol Production Derived From Malignant Testicular Masses: Treatment and Management. Nature Publishing Group. Archived from the original on 13 May 2018. Retrieved 18 April 2015.
  29. Jump up to:a b Loose DS, Kan PB, Hirst MA, Marcus RA, Feldman D (May 1983). “Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes”The Journal of Clinical Investigation71 (5): 1495–9. doi:10.1172/JCI110903PMC 437014PMID 6304148.
  30. ^ Zelefsky MJ, Eastham JA, Sartor OA, Kantoff P (2008). DeVita VT, Lawrence TS, Rosenberg SA (eds.). Cancer: Principles & Practice of Oncology (8th ed.). Philadelphia: Lippincott Williams & Wilkins. p. 1443. ISBN 9780781772075.
  31. ^ Loli P, Berselli ME, Tagliaferri M (December 1986). “Use of ketoconazole in the treatment of Cushing’s syndrome”. The Journal of Clinical Endocrinology and Metabolism63 (6): 1365–71. doi:10.1210/jcem-63-6-1365PMID 3023421.
  32. ^ Thompson IM (2001). “Flare Associated with LHRH-Agonist Therapy”Reviews in Urology3 (Suppl 3): S10–4. PMC 1476081PMID 16986003.
  33. Jump up to:a b c d e f g h i “Ketoconazole tablet”DailyMed. 26 June 2018. Retrieved 5 January 2020.
  34. Jump up to:a b c d e “Nizoral (Ketoconazole): Side Effects, Interactions, Warning, Dosage & Uses”RxList. Retrieved 7 April 2019.
  35. ^ Deepinder F, Braunstein GD (September 2012). “Drug-induced gynecomastia: an evidence-based review”. Expert Opinion on Drug Safety11 (5): 779–95. doi:10.1517/14740338.2012.712109PMID 22862307S2CID 22938364.
  36. Jump up to:a b “Ketoconazole (Nizoral) Use During Pregnancy” Retrieved 24 May 2020.
  37. ^ Kazy Z, Puhó E, Czeizel AE (March 2005). “Population-based case-control study of oral ketoconazole treatment for birth outcomes”Congenital Anomalies45 (1): 5–8. doi:10.1111/j.1741-4520.2005.00053.xPMID 15737124S2CID 41187361.
  38. ^ Cartledge JD, Midgley J, Gazzard BG (December 1997). “Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidosis”. AIDS11 (15): 1839–44. doi:10.1097/00002030-199715000-00008PMID 9412702S2CID 8440973.
  39. ^ Sanglard D, Ischer F, Monod M, Bille J (February 1997). “Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene”Microbiology143 (Pt 2): 405–16. doi:10.1099/00221287-143-2-405PMID 9043118.
  40. ^ Witjes FJ, Debruyne FM, Fernandez del Moral P, Geboers AD (May 1989). “Ketoconazole high dose in management of hormonally pretreated patients with progressive metastatic prostate cancer. Dutch South-Eastern Urological Cooperative Group”. Urology33 (5): 411–5. doi:10.1016/0090-4295(89)90037-XPMID 2652864.
  41. ^ De Coster R, Wouters W, Bruynseels J (January 1996). “P450-dependent enzymes as targets for prostate cancer therapy”. The Journal of Steroid Biochemistry and Molecular Biology56 (1–6 Spec No): 133–43. doi:10.1016/0960-0760(95)00230-8PMID 8603034S2CID 42845713.
  42. ^ Eil C (August 1992). “Ketoconazole binds to the human androgen receptor”Hormone and Metabolic Research24 (8): 367–70. doi:10.1055/s-2007-1003337PMID 1526623.
  43. ^ Loose DS, Stover EP, Feldman D (July 1983). “Ketoconazole binds to glucocorticoid receptors and exhibits glucocorticoid antagonist activity in cultured cells”The Journal of Clinical Investigation72 (1): 404–8. doi:10.1172/jci110982PMC 1129197PMID 6135709.
  44. ^ Duret C, Daujat-Chavanieu M, Pascussi JM, Pichard-Garcia L, Balaguer P, Fabre JM, et al. (July 2006). “Ketoconazole and miconazole are antagonists of the human glucocorticoid receptor: consequences on the expression and function of the constitutive androstane receptor and the pregnane X receptor”Molecular Pharmacology70 (1): 329–39. doi:10.1124/mol.105.022046PMID 16608920S2CID 21455699.
  45. ^ Shaw JC (November 1996). “Antiandrogen therapy in dermatology”. International Journal of Dermatology35 (11): 770–8. doi:10.1111/j.1365-4362.1996.tb02970.xPMID 8915726S2CID 39334280.
  46. Jump up to:a b c d e f Sonino N (August 1986). “The endocrine effects of ketoconazole”. Journal of Endocrinological Investigation9 (4): 341–7. doi:10.1007/BF03346939PMID 3537102S2CID 9148909.
  47. Jump up to:a b Wheeler CJ, Keye WR, Peterson CM (2010). “Polycystic Ovary Syndrome”. Reproductive Endocrinology and Infertility. pp. 147–182. doi:10.1007/978-1-4419-1436-1_11ISBN 978-1-4419-1435-4.
  48. Jump up to:a b c Drobnis EZ, Nangia AK (2017). “Antimicrobials and Male Reproduction”. Advances in Experimental Medicine and Biology1034: 131–161. doi:10.1007/978-3-319-69535-8_10ISBN 978-3-319-69534-1PMID 29256130.
  49. ^ Feldman D (November 1986). “Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis”. Endocrine Reviews7 (4): 409–20. doi:10.1210/edrv-7-4-409PMID 3536461.
  50. ^ Gal M, Orly J, Barr I, Algur N, Boldes R, Diamant YZ (May 1994). “Low dose ketoconazole attenuates serum androgen levels in patients with polycystic ovary syndrome and inhibits ovarian steroidogenesis in vitro”Fertility and Sterility61 (5): 823–32. doi:10.1016/S0015-0282(16)56691-6PMID 8174717.
  51. Jump up to:a b Lønning PE (2009). “New endocrine drugs for treatment of advanced breast cancer”Acta Oncologica29 (3): 379–86. doi:10.3109/02841869009090018PMID 2194539.
  52. ^ Tarbit MH, Robertson WR, Lambert A (1990). “Hepatic and Endocrine Effects of Azole Antifungal Agents”. Chemotherapy of Fungal Diseases. Handbook of Experimental Pharmacology. Vol. 96. pp. 205–229. doi:10.1007/978-3-642-75458-6_10ISBN 978-3-642-75460-9ISSN 0171-2004.
  53. ^ Philippaert K, Kerselaers S, Voets T, Vennekens R (April 2018). “2+-Activated Monovalent Cation-Selective Channels”SLAS Discovery23 (4): 341–352. doi:10.1177/2472555217748932PMID 29316407.
  54. ^ Chin TW, Loeb M, Fong IW (August 1995). “Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole”Antimicrobial Agents and Chemotherapy39 (8): 1671–5. doi:10.1128/AAC.39.8.1671PMC 162805PMID 7486898.
  55. Jump up to:a b c d e Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 720–. ISBN 978-1-4757-2085-3.
  56. Jump up to:a b c d e f Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 586–. ISBN 978-3-88763-075-1.
  57. ^ Heeres J, Backx LJ, Mostmans JH, Van Cutsem J (August 1979). “Antimycotic imidazoles. part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent”. Journal of Medicinal Chemistry22 (8): 1003–5. doi:10.1021/jm00194a023PMID 490531.
  58. ^ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia (3rd ed.). Elsevier. pp. 1997–. ISBN 978-0-8155-1856-3.
  59. Jump up to:a b Golan DE (2008). Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. Lippincott Williams & Wilkins. pp. 624–. ISBN 978-0-7817-8355-2.
  60. ^ “Ketoconazole HRA”European Medicines Agency (EMA). 17 September 2018. Retrieved 1 April 2020.
  61. ^ “Levoketoconazole – Strongbridge Biopharma – AdisInsight”.
  62. ^ Fleseriu M, Castinetti F (December 2016). “Updates on the role of adrenal steroidogenesis inhibitors in Cushing’s syndrome: a focus on novel therapies”Pituitary19 (6): 643–653. doi:10.1007/s11102-016-0742-1PMC 5080363PMID 27600150.
  63. Jump up to:a b Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 159–. ISBN 978-94-011-4439-1.
  64. Jump up to:a b c “Ketoconazole”.
  65. ^ “European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole”Press Release. European Medicines Agency. 26 July 2013. Archived from the original on 14 January 2014.
  66. ^ KuKanich B (January 2008). “A review of selected systemic antifungal drugs for use in dogs and cats”Veterinary MedicineArchived from the original on 5 October 2013.